about
sameAs
Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of ParkinsonismBiochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimersDifferential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathwaysInsight into the mode of action of the LRRK2 Y1699C pathogenic mutantA direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylationThe Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sitesIdentification of protein phosphatase 1 as a regulator of the LRRK2 phosphorylation cycleThe Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylationUnbiased screen for interactors of leucine-rich repeat kinase 2 supports a common pathway for sporadic and familial Parkinson diseaseLeucine-rich repeat kinase 2 interacts with p21-activated kinase 6 to control neurite complexity in mammalian brainAutomated quantitative gait analysis in animal models of movement disorders.The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylationImmunohistochemical detection of transgene expression in the brain using small epitope tags.Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.Role of LRRK2 in the regulation of dopamine receptor traffickingLRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding.MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.Metabolic labeling of leucine rich repeat kinases 1 and 2 with radioactive phosphate.On the road to leucine-rich repeat kinase 2 signalling: evidence from cellular and in vivo studies.Kinases as targets for Parkinson's disease: from genetics to therapy.Phosphorylation of LRRK2: from kinase to substrate.Deregulation of protein translation control, a potential game-changing hypothesis for Parkinson's disease pathogenesis.Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes.LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2.LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker?In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2.Chemical genetic approach identifies microtubule affinity-regulating kinase 1 as a leucine-rich repeat kinase 2 substrate.Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradationResistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.Detailed localization of regulator of G protein signaling 2 messenger ribonucleic acid and protein in the rat brain.Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions.Dopamine receptor-mediated regulation of RGS2 and RGS4 mRNA differentially depends on ascending dopamine projections and time.MK-801 alters RGS2 levels and adenylyl cyclase sensitivity in the rat striatum.Distribution of PINK1 and LRRK2 in rat and mouse brain.Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain.Indolinone based LRRK2 kinase inhibitors with a key hydrogen bond.Bilateral control of brain activity by dopamine D1 receptors: evidence from induction patterns of regulator of G protein signaling 2 and c-fos mRNA in D1-challenged hemiparkinsonian rats.
P50
Q21131229-6A86769B-93B6-475C-9759-967C78F8EBB0Q24298093-47592DDA-0664-46BD-A664-7586ADEED81EQ24299578-2E711DFC-3DB8-42AD-B976-09D9A4FE50C4Q24306788-CCDA753A-FA6B-4B3B-B44F-E37E981305EDQ24310126-794F2912-F2D0-46A9-B4BC-420678519A7EQ24313336-685E83F8-2668-4CA6-8598-5DE3BB893A68Q24317158-953FCA7C-6BF6-4FE0-9C64-A992461EDFB3Q24318533-36A565BF-142A-41BF-813A-BDF0E97B7A45Q24336432-3307ABF5-F0CA-4747-92D0-DED4259D494CQ28267434-C699D54A-BEE5-4CBB-B6E8-6B9399D0FE60Q30496179-DAD707B4-C6F4-4174-8864-B72783769CEFQ33525587-7CC071FC-AA59-4ADB-9EC0-E71A8675E416Q33532297-E1AAA0DA-29EC-45DF-8C14-0D2266BCBC08Q33595218-CE971890-094D-4FD5-A418-A925EFA55858Q33764887-C9F9EE86-5630-41C2-B17D-8C246AA622D2Q33999270-8A7D775A-FF40-461E-AEFF-39097AB840F8Q36525872-9288A4DF-0C31-4DF4-83C7-7302D74B9776Q37582415-B8469F3D-5350-4B84-8DA0-A2761F297597Q37856642-9C7C9F21-7382-4C84-94BB-C9CEF624413DQ37916644-C0942811-A7AF-4D79-98C5-4C8663ED6F55Q38044439-98726B71-1FA5-477D-A7B4-CD89C6185BA4Q38532397-D8CC9463-FDD5-4639-8F11-9223543C80B9Q38619109-B8EFEF89-CD95-44E8-90BE-3286F00070C4Q38620229-213ACEEB-4863-4F11-BEE7-7C9BE9082F45Q38814476-880C84C0-3DC9-4937-920B-F138F9D8AE89Q39137378-BF08443A-8BB2-4DEF-BF2F-EA70B198467FQ40188432-D3F9BACA-C4CC-46BA-80B6-25E297F884AAQ41099991-08A6EFB8-2BA0-4F96-941B-93104A34A4E7Q41163700-D436F66E-F65D-4316-8739-575C822C1D05Q42275343-09F1BEE4-192B-4AD4-9C34-375A1446BDC5Q42525479-24EC34AA-3D7E-4F64-A244-EF23A90342F2Q43158706-533ABAA3-F4B4-4054-8379-4D640C437F9AQ44326527-34F315AB-9280-49AC-9B8A-ECB7663AA407Q44847937-DC9988EE-3AF1-4BFD-A597-751660F52629Q45239055-D4439418-9970-47AF-804A-F47A6453B66AQ45859017-F86CFE01-F831-4263-A490-5C921BA3315AQ45865514-B61DE862-7FD7-4310-8F4D-405F3E8C8EDEQ45866495-BCB3F3F7-4F02-403C-B198-9C2DEF2BFC27Q45868576-7D6B551A-CB81-4655-B831-049515B7B845Q46554796-422BBA99-4002-44F7-8EE7-3BB64995B620
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Jean-Marc Taymans
@ast
Jean-Marc Taymans
@en
Jean-Marc Taymans
@es
Jean-Marc Taymans
@nl
Jean-Marc Taymans
@sl
type
label
Jean-Marc Taymans
@ast
Jean-Marc Taymans
@en
Jean-Marc Taymans
@es
Jean-Marc Taymans
@nl
Jean-Marc Taymans
@sl
altLabel
Taymans JM
@en
prefLabel
Jean-Marc Taymans
@ast
Jean-Marc Taymans
@en
Jean-Marc Taymans
@es
Jean-Marc Taymans
@nl
Jean-Marc Taymans
@sl
P106
P1153
6602647144
P2038
Jean-Marc_Taymans
P21
P2798
P31
P3762
P4012
P496
0000-0001-5503-5524